Literature DB >> 3947037

Intravenous lisuride corrects oscillations of motor performance in Parkinson's disease.

J A Obeso, M R Luquin, J M Martínez Lage.   

Abstract

Seventeen lisuride infusions were given to 12 patients with Parkinson's disease who showed daily oscillations in motor performance. The mean lisuride dose given in continuous intravenous infusion was 0.59 mg (range, 0.3 to 1.0 mg) during a mean period of 9.0 hours (range, 5 to 12 hours). A significant reduction in the number of hours "off" was obtained in all patients. Additional oral levodopa was necessary to maintain normal mobility throughout the infusions. Severe hypotension occurred in 2 patients which required termination of the infusions. Five patients experienced nausea, sweating, and malaise but this did not necessitate interruption of the infusions. Lisuride appears to be one of the best available dopamine agonists for continuous dopaminergic stimulation.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3947037     DOI: 10.1002/ana.410190107

Source DB:  PubMed          Journal:  Ann Neurol        ISSN: 0364-5134            Impact factor:   10.422


  8 in total

Review 1.  Clinical pharmacokinetics of anti-parkinsonian drugs.

Authors:  J M Cedarbaum
Journal:  Clin Pharmacokinet       Date:  1987-09       Impact factor: 6.447

Review 2.  Clinical pharmacokinetic and pharmacodynamic properties of drugs used in the treatment of Parkinson's disease.

Authors:  Dirk Deleu; Margaret G Northway; Yolande Hanssens
Journal:  Clin Pharmacokinet       Date:  2002       Impact factor: 6.447

3.  Efficacy of sinemet CR4 in subgroups of patients with Parkinson's disease.

Authors:  S A Factor; J R Sanchez-Ramos; W J Weiner; A M Ingenito
Journal:  J Neurol Neurosurg Psychiatry       Date:  1989-01       Impact factor: 10.154

Review 4.  Levodopa-induced dyskinesias and their management.

Authors:  Francesca Del Sorbo; Alberto Albanese
Journal:  J Neurol       Date:  2008-08       Impact factor: 4.849

Review 5.  Methods of managing levodopa-induced dyskinesias.

Authors:  L T Giron; W C Koller
Journal:  Drug Saf       Date:  1996-06       Impact factor: 5.606

6.  Low dose lisuride in advanced Parkinson disease.

Authors:  F Degl'Innocenti; A Ginanneschi; S Magnolfi; L Catarzi; P Marini
Journal:  Ital J Neurol Sci       Date:  1987-08

7.  Comparison of the clinical pharmacology of (-)NPA and levodopa in Parkinson's disease.

Authors:  M M Mouradian; I J Heuser; F Baronti; M Giuffra; K Conant; T L Davis; T N Chase
Journal:  J Neurol Neurosurg Psychiatry       Date:  1991-05       Impact factor: 10.154

8.  Selective D-1 dopamine receptor agonist treatment of Parkinson's disease.

Authors:  A Braun; G Fabbrini; M M Mouradian; C Serrati; P Barone; T N Chase
Journal:  J Neural Transm       Date:  1987       Impact factor: 3.575

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.